Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Retrospective Evaluation Of Insurance Status As It Relates To Outcomes In Diffuse Large B-Cell Lymphoma

Bryan J Little, MPH, Julio C Chavez, MD, Celeste M. Bello, MD, Paul Chervenick, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Bijal D. Shah, MD

Blood (2013) 122 (21): 1702.

https://doi.org/10.1182/blood.V122.21.1702.1702

Published: 2013

Journal Articles

A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prognostic Index (A-IPI)

Samir Dalia, MD, Julio C Chavez, MD, Celeste M. Bello, MD, Paul A. Chervenick, MD, Bryan J Little, MPH, Najla H Al Ali, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Ji-Hyun Lee, PhD, Kate Fisher, MA, Zachary Thompson, PhD, Bong-jin Choi, MA, Bijal D. Shah, MD

Blood (2013) 122 (21): 4267.

https://doi.org/10.1182/blood.V122.21.4267.4267

Published: 2013

Journal Articles

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Asmita Mishra, MD, Jeffrey E Lancet, MD, Najla H Al Ali, Eric Padron, MD, Viet Q. Ho, PharmD, BCOP, Bryan J Little, Javier Pinilla-Ibarz, MD, PhD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 2815.

https://doi.org/10.1182/blood.V120.21.2815.2815

Published: 2012

Journal Articles

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

Asmita Mishra, MD, Najla H Al Ali, Maria Corrales-Yepez, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Mohamed A Kharfan-Dabaja, MD, Javier Pinilla-Ibarz, MD, PhD, Bryan J Little, Jeffrey E Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 2816.

https://doi.org/10.1182/blood.V120.21.2816.2816

Published: 2012

Journal Articles

Autologous Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

Bijal D. Shah, MD, Bryan J Little, MPH, Jennifer Cultrera, MD, Celeste M. Bello, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Marcie Tomblyn, MD, MS, Ernesto Ayala, MD

Blood (2012) 120 (21): 4542.

https://doi.org/10.1182/blood.V120.21.4542.4542

Published: 2012

Journal Articles

Cytarabine Either with Induction or Conditioning May Improve Outcomes Among Those Undergoing Autologous Transplantation in First or Second Remission for Mantle Cell Lymphoma

Bijal D. Shah, MD, Bryan J Little, MPH, Jennifer Cultrera, MD, Celeste M. Bello, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Marcie Tomblyn, MD, MS, Ernesto Ayala, MD

Blood (2012) 120 (21): 4546.

https://doi.org/10.1182/blood.V120.21.4546.4546

Published: 2012

Journal Articles

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Rami S. Komrokji, MD, Najla H Al Ali, Asmita Mishra, MD, Maria Corrales-Yepez, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Bryan J Little, Javier Pinilla-Ibarz, MD, PhD, Jeffrey E Lancet, MD, Alan F. List, MD

Blood (2012) 120 (21): 3852.

https://doi.org/10.1182/blood.V120.21.3852.3852

Published: 2012

NARROW

A Retrospective Evaluation Of Insurance Status As It Relates To Outcomes In Diffuse Large B-Cell Lymphoma

A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prognostic Index (A-IPI)

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

Autologous Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

Cytarabine Either with Induction or Conditioning May Improve Outcomes Among Those Undergoing Autologous Transplantation in First or Second Remission for Mantle Cell Lymphoma

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Email alerts

ASH Publications

American Society of Hematology

A Retrospective Evaluation Of Insurance Status As It Relates To Outcomes In Diffuse Large B-Cell Lymphoma

A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prognostic Index (A-IPI)

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

Autologous Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

Cytarabine Either with Induction or Conditioning May Improve Outcomes Among Those Undergoing Autologous Transplantation in First or Second Remission for Mantle Cell Lymphoma

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only